Litigation Details for BURLINGTON DRUG CO., INC. v. PFIZER INC. (D.N.J. 2012)
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
BURLINGTON DRUG CO., INC. v. PFIZER INC. (D.N.J. 2012)
| Docket | See Plans and Pricing | Date Filed | 2012-04-23 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 15:1 Antitrust Litigation | Assigned To | Peter G. Sheridan |
| Jury Demand | Both | Referred To | Douglas Arpert |
| Patents | 6,126,971; 6,455,574; 6,503,894; 7,276,250; 7,851,482; 8,309,060; 8,309,122; 8,329,216; 8,808,737; 8,871,779 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BURLINGTON DRUG CO., INC. v. PFIZER INC.
The small molecule drugs covered by the patents cited in this case are See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , See Plans and Pricing , and See Plans and Pricing .
Details for BURLINGTON DRUG CO., INC. v. PFIZER INC. (D.N.J. 2012)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2013-09-05 | 455 | Order on Motion to Dismiss | Reissue Patent No. 40,667 (the “RE ‘667 patent’”)); U.S. Patent No. 6,126,971 (the “‘971 patent”); U.S….S. Patent No. 5,686,104 (the “‘104 patent”); U.S. Patent No. 6,087,511 (the “‘511 patent”); U.S. Patent… Patent No. 6,274,740 (the “‘740 patent”); and U.S. Patent No. 5,969,156 (the “‘156 patent”). See, …4,681,893 (the “‘893 patent”); U.S. Patent No. 5,273,995 (the “‘995 patent,” reissued in part as U.S. Reissue…particular Lipitor Patent – the ‘995 patent – as well as its relationship to the ‘893 patent. Compl. ¶¶ | External link to document |
| 2014-09-12 | 566 | Memorandum | Reissue Patent No. 40,667); U.S. Patent No. 6,126,971 (the “‘971 patent”); U.S. Patent No. 5,686,104 (the…the “‘104 patent”); U.S. Patent No. 6,087,511 (the “‘511 patent”); U.S. Patent No. 6,274,740 (the “…back up” patents — the ‘156 patent, the two Formulation Patents (the ‘971 and ‘104 patents), and the…exclusive licensee of the ’995 patent and other patents (need full cite of patent). At all relevant times…4,681,893 (the “‘893 patent”); U.S. Patent No. 5,273,995 (the “‘995 patent,” reissued later as U.S. Reissue | External link to document |
| 2018-08-17 | 812 | Letter | 6,503,894 ("'894 patent") for a brand-name testosterone…the ’122 patent”); Patent No. 8,329,216 (“the ’216 patent”); Patent No. 8,808,737 (“the ’737 patent…the ’250 patent”), 5,662,933 (“the ’933 patent”), and 5,958,456 (“the ’456 patent”) (“the…proposed broadening the patent license in the SLA to “any patents and patent applications owned… the patent[s], not just the patent [at issue] today, but cover all future patent[s] as | External link to document |
| 2018-09-20 | 815 | Amended Complaint | following patents in the Orange Book as covering Lipitor: 6,126,971 (the “’971 Patent”); 5,686,104… 6,126,971 (the “’971 Patent,” expiry November 11, 2014). Both the ’104 and ’971 Patents cover …follow-on patent (U.S. Patent Number 5,273,995, the “’995 Enantiomer Patent” or the “’995 Patent” or the… and patent applicant of both the ’893 Patent and the duplicative follow-on patent. Both patents issued…Stabilization Formulation Patents, the ’156 Patent, the ’995 Patent, and ’667 Patent), baseless sham litigation | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
